Graves' disease: high NLR predicts relapse after antithyroid drug therapy

  • Kim M & al.
  • Endocrine
  • 20 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A high neutrophil-to-lymphocyte ratio (NLR) is associated with relapse in patients with Graves' disease treated with antithyroid drug (ATD) therapy.

Why this matters

  • Prognostic markers can help guide patient management, and the NLR is simple, noninvasive, and cost-effective.

Key results

  • 21% of patients experienced relapse within a year of ATD withdrawal.
  • Patients with high NLR (≥1.14) had shorter relapse-free survival (RFS) compared with patients with low NLR (
  • High NLR was associated with an increased risk for relapse compared with low NLR in multivariate analysis (OR, 4.22; P=.016).
  • Young age at the time of diagnosis was also associated with risk for relapse (OR, 4.20; P=.017).

Study design

  • 108 patients with Graves' disease who received ATD therapy were analyzed for relapse/RFS and associated factors.
  • Funding: None disclosed.

Limitations

  • Retrospective study.